Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

A trio of industry stalwarts have told attendees at Swiss Biotech Day that licensing opportunities in China are not limited to the big players in pharma.

The deal advances Angelini’s broader strategy of building scale in brain health and rare neurological disorders through acquisitions, licensing and partnerships.

The drugmaker reported total first quarter sales of $6.9bn, up 5%, with high expectations for HIV PrEP drug Yeztugo and the potential new CAR-T therapy, anito-cel, for multiple myeloma.

Argenx and Insmed turned in double-digit revenue growth in the first quarter, while Sarepta said it is stabilizing the business this year and continuing to forecast lower sales.

Mirum unveiled positive Phase IIb data for volixibat in primary sclerosing cholangitis and licensed an ultra-rare disease asset from Incyte that is under FDA review.